AIDS 2014 featured analyses of data on the potential relationship between hormonal contraceptives and risk of HIV infection. Researchers Charles Morrison (FHI 360) and Kristin Wall (Emory University), and Mary Lyn Gaffield from the WHO discussed the newest findings and guidance.
Data and Uncertainty: Understanding updates on hormonal contraceptives and HIV
The Research to Rollout Timeline for Pre-Exposure Prophylaxis(PrEP)
There is a complex process for new prevention options to move from evidence of benefit in a clinical trial to being available to the public for use. This infographic traces milestones in recent years along the path from research to rollout of pre-exposure prophylaxis (PrEP). The timeline plots key dates for four major clinical trials and related guidance and regulatory decisions.
Microbicide Clinical Trials Timeline
This graphic from AVAC’s Microbicides by the Numbers one-pager tracks major ongoing and completed microbicide trials. It shows the trials that have provided the current evidence about tenofovir gel as well as planned gel and ring trials.
Microbicide Products Currently in Clinical Trials
This graphic from AVAC’s Microbicides by the Numbers one-pager shows the different products currently being studied and how advanced the research is.
Progress in VMMC Scale-up in Priority Countries
This map shows progress made through 2013 towards the target of circumcising 80% of eligible men in 14 priority countries. It is particularly useful as a tool for advocates to show how their country’s VMMC program compares to others in East and Southern Africa.
Global Investment in HIV Cure Research and Development in 2013
The International AIDS Society HIV Cure Resource Tracking group joined with the HIV Vaccines and Microbicides Tracking Working Group to estimate global investments in HIV cure research and produce this short report.
HIV Prevention Research & Development Investment in 2013: In a changing global development, economic and human rights landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The report shows that investment in HIV prevention research fell 4 percent in 2013, due to a combination of factors including declining investments by the United States and European donors, changes in the international development landscape and changes in the pipeline of HIV prevention products being tested.
When do you stop an HIV prevention trial for futility? A primer for HIV prevention advocates
This fact sheet looks at why trials are stopped early for “futility.” What does this mean, when is such a recommendation made and how does it affect other ongoing trials?
Jeff McConnell Memorial Webinar – Audio
This webinar memorialized pioneering sociologist Jeff McConnell and his impact on HIV prevention science. Updates were presented on pre-exposure prophylaxis (PrEP) research and the implications of Dr. McConnell’s research on sexual networks for how PrEP will be implemented.Find details, slides and full flash webinar here.
HIV Prevention Europe Webinars: Rectal microbicides
The seventh webinar in our series addressing a range of topics in HIV prevention research, hosted jointly by NAM and AVAC, focused on rectal microbicides. Speakers included: Ian McGowan, University of Pittsburgh; Carolina Herrera, Imperial College; Alex Carballo-Dieguez, Columbia University; and Marc-André LeBlanc, IRMA.
The presentation was followed by a Q&A session. Click here for slides and audio from the webinar.